Related Experiment Video

Updated: Aug 14, 2026

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens
09:26

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens

Published on: July 29, 2011

Mitogenic signal transduction pathways in meningiomas: novel targets for meningioma chemotherapy?

Mahlon Johnson1, Steven Toms

  • 1Department of Pathology, University of Tennessee, Graduate School of Medicine, Knoxville, Tennessee 37920, USA. mdjohnso@mc.utmk.edu

Journal of Neuropathology and Experimental Neurology
|December 2, 2005
PubMed

Insights

This review explores growth factor pathways in meningiomas, focusing on their roles in tumor growth and apoptosis. It highlights potential therapeutic targets within these signaling cascades for neuro-oncology applications.

Area of Science:

  • Neuro-oncology
  • Molecular biology
  • Cancer research

Background:

  • Growth factor receptors and downstream pathways are crucial in neuro-oncology.
  • These pathways are well-studied in gliomas but less understood in meningiomas.

Purpose of the Study:

  • To review current research on growth factor signaling pathways in meningioma growth.
  • To identify potential therapeutic targets within these pathways.

Main Methods:

  • Literature review of research on meningioma growth pathways.
  • Analysis of signaling cascades including MAPK, PI3K-Akt, and TGF-beta.

Main Results:

  • Several key pathways (Ras-Raf-1-MAPK, PI3K-Akt, PLC-gamma1-PKC, phospholipase A2-cyclooxygenase, TGF-beta-Smad) appear to regulate meningioma growth.
  • These pathways also seem to inhibit apoptosis in meningiomas.

Conclusions:

  • Understanding these pathways is vital for meningioma treatment.
  • Specific sites within these cascades represent potential targets for novel therapies.

More Related Videos

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor09:33

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Published on: August 25, 2023

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...